Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.
Introduced
Mar 4, 2025
Last Action
Mar 4, 2025
Session
119th Congress
Sponsors
1 primary · 7 co
Passage Probability
2% — Very Low
Introduced in Senate
Read twice and referred to the Committee on Finance.
Get a plain-English explanation of what this bill does, who it affects, and why it matters.
2%
Estimate based on legislative signals
See what factors are driving this score — cosponsor support, bipartisan backing, committee progress, and more.
Upgrade to ProRead twice and referred to the Committee on Finance.